Krystal Biotech

Krystal Biotech, Inc. is a pioneering biotechnology company that specializes in developing transformative gene therapies for patients with severe, life-threatening, or rare diseases. Committed to addressing unmet medical needs, Krystal focuses on creating redosable gene therapies, which provide patients with innovative treatment options. Its flagship product, VYJUVEK®, is the first and only redosable gene therapy specifically designed for dystrophic epidermolysis bullosa, showcasing the company's dedication to developing solutions for challenging medical conditions.

With a robust and extensive pipeline of genetic therapies, Krystal Biotech aims to correct the root causes of serious diseases that currently have limited or no approved treatments. The company's proprietary platform is based on a modified and engineered HSV-1 vector that is replication-defective and non-integrating. This platform allows Krystal to manufacture effective gene therapies through its two state-of-the-art Good Manufacturing Practice (GMP) facilities, ensuring that they meet high standards of safety and efficacy. Overall, Krystal Biotech's mission is to redefine the landscape of gene therapy through focused research, innovative product development, and patient-centered healthcare, making a significant impact in the biopharmaceutical industry.